{"id":"W2794302045","doi":"10.3747/co.25.4005","title":"Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Untreated Chronic Lymphocytic Leukemia","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Fluidigm (Canada); Vancouver General Hospital; University of British Columbia; BC Cancer Agency; Foothills Medical Centre; Impact; University of Calgary","funders":"University of Texas MD Anderson Cancer Center; Lundbeck Canada; Gilead Sciences; AstraZeneca","keywords":"Ibrutinib; Obinutuzumab; Medicine; Bendamustine; Fludarabine; Venetoclax; Chronic lymphocytic leukemia; Rituximab; Internal medicine; Oncology; IGHV@; Alemtuzumab; Hematology; Cyclophosphamide; Minimal residual disease; Lymphoplasmacytic Lymphoma; Leukemia; Lymphoma; Chemotherapy; Waldenstrom macroglobulinemia; Transplantation","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05257216,0.0016081,0.002233671,0.00973375,0.003304203,0.006694801,0.003440366,0.008663859,0.01266442],"category_scores_gemma":[0.129026,0.001099637,0.001689996,0.01111451,0.0018238,0.004225359,0.003872765,0.008892582,0.004821505],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01166257,"about_ca_system_score_gemma":0.04221276,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04661094,"about_ca_topic_score_gemma":0.1523734,"domain_scores_codex":[0.9760153,0.007139297,0.004674066,0.0007766124,0.009808308,0.001586567],"domain_scores_gemma":[0.7149961,0.05422645,0.02495654,0.006720066,0.1686115,0.03048943],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003591093,0.00002795517,0.000940427,0.0006030366,0.00001968509,0.00003560729,0.00006779299,0.00001923118,0.00006366212,0.0001076532,0.9686425,0.02943652],"study_design_scores_gemma":[0.00008676266,0.00003984394,0.007169828,0.003018161,0.00006905339,0.0001081502,0.000273559,0.00003890144,0.00007644083,0.0004421257,0.9886446,0.00003253625],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.001483532,0.06217659,0.001666122,0.6896039,0.2145041,0.001246506,0.007580775,0.0004948715,0.02124357],"genre_scores_gemma":[0.01449519,0.1582806,0.01790627,0.3953468,0.3586225,0.003090092,0.02206715,0.0004762261,0.0297152],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.05257216,"threshold_uncertainty_score":0.2780315,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1390697712462306,"score_gpt":0.4710770174048208,"score_spread":0.3320072461585902,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}